Benign breast diseases, contraception and hormone replacement therapy

Minerva Ginecologica

Volumn 64, Issue 1, 2012, Pages 67-74

  Gadducci, A ^a   Guerrieri, M E ^a   Genazzani, A R ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Breast cyst; Breast neoplasms; Contraceptives, oral; Fibroadenoma; Fibrocystic breast disease; Hormone replacement therapy

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; C REACTIVE PROTEIN; EPIDERMAL GROWTH FACTOR; ESTROGEN RECEPTOR ALPHA; KALLIKREIN; MYC PROTEIN; ORAL CONTRACEPTIVE AGENT; PROTEIN BCL 2; STEROID HORMONE; TRANSFORMING GROWTH FACTOR BETA;

ASPIRATION BIOPSY; BODY MASS; BODY WEIGHT; BREAST BIOPSY; BREAST CANCER; BREAST FIBROADENOMA; BREAST HYPERPLASIA; CANCER RISK; DISEASE ASSOCIATION; FAMILY HISTORY; FIBROCYSTIC BREAST DISEASE; FOLLICULAR PHASE; GENETIC POLYMORPHISM; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; LONG TERM CARE; LUTEAL PHASE; OBESITY; ORAL CONTRACEPTION; POSTMENOPAUSE; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; TUMOR VOLUME; WEIGHT GAIN;

BREAST DISEASES; CONTRACEPTIVES, ORAL; FEMALE; FIBROCYSTIC BREAST DISEASE; HORMONE REPLACEMENT THERAPY; HUMANS;

EID: 84860247272     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Goehring C, Morabia A. Epidemiology of benign breast disease, with special attention to histologic types. Epidemiol Rev 1997;19:310-27. (Pubitemid 28099778)
2. Sismondi P, Defabiani E, Biglia N, Ponzone R, Cacciari F, Actis Dato F et al. Benign breast disease: a non disease?. In "Pediatric and. Adolescent gynecology" (Bruni V, Dei M, Eds), CIC Edizioni Internazionali, Rome 2003, 160-70.
3. Hughes LE, Mansel RE, Webster DJ. Aberrations of normal development and involution (ANDI): a new perspective on pathogenesis and nomenclature of benign breast disorders. Lancet 1987;2:1316-9. (Pubitemid 17156645)
4. Friedenreich C, Bryant H, Alexander F, Hugh J, Danyluk J, Page D. Risk factors for benign proliferative breast disease. Int J Epidemiol 2000;29:637-44. (Pubitemid 30612229)
5. El-Wakeel H, Umpleby HC. Systematic review of fibroadenoma as a risk factor for breast cancer. Breast 2003;12:302-7. (Pubitemid 37322060)
6. Dupont WD, Page DL, Parl FF, Vnencak-Jones CL, Plummer WD Jr, Rados MS et al. Long-term risk of breast cancer in women with fibroadenoma N Engl J Med 1994;331:10-5. (Pubitemid 24195594)
7. Cericatto R, Pozzobon A, Morsch DM, Menke CH, Brum IS, Spritzer PM. Estrogen receptor-alpha, bcl-2 and c-myc gene expression in fibroadenomas and adjacent normal breast: association with nodule size, hormonal and reproductive features. Steroids 2005;70:153-60. (Pubitemid 40342608)
8. Hutchinson WB, Thomas DB, Hamlin WB, Roth GJ, Peterson AV, Williams B. Risk of breast cancer in women with benign breast disease. J Natl Cancer Inst 1980;65:13-20. (Pubitemid 10071590)
9. Moskowitz M, Gartside P, Wirman JA, McLaughlin C. Proliferative disorders of the breast as risk factors for breast cancer in a self-selected screened population: pathologic markers. Radiology 1980;134:289-91. (Pubitemid 10178047)
10. Carter CL, Corle DK, Micozzi MS, Schatzkin A, Taylor PR. A prospective study of the development of breast cancer in 16,692 women with benign breast disease. AmJ Epidemiol 1988;128:467-77.
11. McDivitt RW, Stevens JA, Lee NC, Wingo PA, Rubin GL, Gersell D. Histologic types of benign breast disease and the risk for breast cancer. Cancer 1992;69:1408-14.
12. Krieger N, Hiatt RA. Risk of breast cancer after benign breast diseases: variation by histologic type, degree of atypia, age at biopsy, and length of follow-up. Am J Epidemiol 1992;135:619-31.
13. McDivitt RW, Stevens JA, Lee NC, Wingo PA, Rubin GL, Gersell D. Histologic types of benign breast disease and the risk for breast cancer. The Cancer and Steroid Hormone Study Group Cancer 1992;69:1408-14.
14. Piragine G,Coopmans de Yoldi G,Bergonzi S, Ferranti C. Le affezioni mammarie benigne. In: Veronesi U, Coopmans de Yoldi G, editors. Senologia diagnostica per immagine. Pavia: EDIMES Edizioni Medico-Scientifiche; 2011. p. 116-33.
15. Friedenreich C, Bryant H, Alexander F, Hugh J, Danyluk J, Page D. Risk factors for benign proliferative breast disease. Int J Epidemiol 2000;29:637-44. (Pubitemid 30612229)
16. .Mannello F, Tonti GA. Benign breast diseases: classification, diagnosis, and management. Oncologist 2006;11:1132-4. (Pubitemid 44788405)
17. Leis HPJr. Gross breast cysts: significance of apocrine type, identification by cyst fluid analysis, and management. Breast Dis 1993;6:185-94.
18. Gomes C, Amaral N, Marques C, Borralho R, de Oliveira CF. Sclerosis of gross cysts of the breast:a three-year study. Eur J Gynaecol Oncol 2002;23:191-4. (Pubitemid 34632566)
19. Miller WR, Dixon JM, Scott WN, Forrest AP. Classification of human breast cysts according to electrolyte and androgen conjugate composition. Clin Oncol 1983;9:227-32. (Pubitemid 13006198)
20. Naldoni C, Costantini M, Dogliotti L, Bruzzi P, Bucchi L, Buzzi G et al. Association of cyst type with risk factors for breast cancer and relapse rate in women with gross cystic disease of the breast. Cancer Res 1992;52:1791-5.
21. Weber CJ, Kim D, Costanzo M, Morris J, Howe B, Ward L et al. Relationships of Na+ and K+ concentrations to GRP, CGRP, and calcitonin immunoreactivities and Na+,K(+)-ATPase (NKA) inhibitory activity in human breast cyst fluid. Ann Surg Oncol 1994;1:339-44.
22. Zanardi S, Pensa F, Torrisi R, de Franchis V, Barreca A, Minuto F et al. Presence and distribution of growth factors in breast cyst fluid. Ann N Y Acad Sci 1996;784:542-9. (Pubitemid 26194804)
23. Budai B, Számel I, Sulyok Z, Németh M, Bak M, Kralovánszky J et al. Influence of hormonal status of patients with cystic disease on the composition of cyst fluid and breast cancer risk. Anticancer Res 2000;20:3879-86. (Pubitemid 32002291)
24. Mannello F, Gazzanelli G. Prostate-specific antigen (PSA/hK3):a further player in the field of breast cancer diagnostics? Breast Cancer Res 2001;3:238-43. (Pubitemid 32631703)
25. Boccardo F, Marenghi C, Ghione G, Pepe A, Parodi S, Rubagotti A. Intracystic epidermal growth factor level is predictive of breast-cancer risk in women with gross cystic disease of the breast. Int J Cancer 2001;95:260-5. (Pubitemid 32592094)
26. Mannello F, Tonti GA, Papa S. Human gross cyst breast disease and cystic fluid: bio-molecular, morphological, and clinical studies. Breast Cancer Res Treat 2006;97:115-29.
27. Parish DC, Ghilchik MW, Day JM, Eaton J, Purohit A, Reed MJ. Cytokines in human breast cyst fluid. J Steroid Biochem Mol Biol 2007;104:241-5. (Pubitemid 46901029)
28. Lai LC, Siraj AK, Erbas H, Lennard TWJ. Relationship between basicfibroblast growth factor and transforming growth factor beta 2 in breast cyst fluid. J Clin Endocrinol Metab 1995;80:7115.
29. Hutter RVP. Good-bye to "fibrocystic disease." N Engl J Med 1985;312:179-81.
30. Bodian CA, Lattes R, Perzin KH. The epidemiology of gross cystic disease of the breast confirmed by biopsy or by aspiration of cyst fluid. Cancer Detect Prev 1992;16:7-15.
31. Mannello F, Malatesta M, Gazanelli G. Breast cancer in women with palpable breast cysts. Lancet 1999;354:677-8. (Pubitemid 29391443)
32. Dixon JM, McDonald C, Elton RA, Miller WR. Risk of breast cancer in women with palpable breast cysts:a prospective study. Edinburgh Breast Group. Lancet 1999;353:1742-5. (Pubitemid 29240372)
33. Ciatto S, Biggeri A, Rosselli Del Turco M, Bartoli D, Iossa A. Risk of breast cancer subsequent to proven gross cystic disease. Eur J Cancer 1990;26:555-7. (Pubitemid 20259326)
34. Bundred NJ, West RR, Dowd JO, Mansel RE, Hughes LE. Is there an increased risk of breast cancer in women who have had a breast cyst aspirated? Br J Cancer 1991;64:953-5.
35. Bruzzi P, Dogliotti L, Naldoni C, Bucchi L, Costantini M, Cicognani A et al. Cohort study of association of risk of breast cancer with cyst type in women with gross cystic disease of the breast. BMJ 1997;314:925-8. (Pubitemid 27140215)
36. Hughes LE, Mansel RE, Webster DJ. Aberrations of normal development and involution (ANDI):a new perspective on pathogenesis and nomenclature of benign breast disorders. Lancet 1987;2(8571):1316-9. (Pubitemid 17156645)
37. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312:146-51. (Pubitemid 15192861)
38. Shaaban AM, Sloane JP, West CR, Moore FR, Jarvis C, Williams EM et al. Histopathologic types of benign breast lesions and the risk of breast cancer: case-control study. Am J Surg Pathol 2002;26:421-30. (Pubitemid 34280114)
39. Brinton LA, Vessey MP, Flavel R, Yeates D. Risk factors for benign breast disease. Am J Epidemiol 1981;113:203-14. (Pubitemid 11152571)
40. Cole P, Elwood JM, Kaplan SD. Incidence rates and risk factors of benign breast neoplasms. Am J Epidemiol 1978;108:112-20. (Pubitemid 9148064)
41. Soini I, Aine R, Lauslahti K, Hakama M. Independent risk factors of benign and malignant breast lesions. AmJ Epidemiol 1981;114:507-14. (Pubitemid 11013085)
42. Simard A, Vobecky J, Vobecky JS. Nutrition and lifestyle factors in fibrocystic disease and cancer of the breast. Cancer Detect Prev 1990;14:567-72.
43. Hislop TG, Band PR, Deschamps M, Ng V, Coldman AJ, Worth AJ et al. Diet and histologic types of benign breast disease defined by subsequent risk of breast cancer. Am J Epidemiol 1990;131:263-7.
44. Gallicchio L, McSorley MA, Newschaffer CJ, Huang HY, Thuita LW, Hoffman SC et al. Body mass, polymorphisms in obesity-related genes, and the risk of developing breast cancer among women with benign breast disease. Cancer Detect Prev 2007;31:95-101. (Pubitemid 46669815)
45. Djuric Z, Edwards A, Madan S, Darga L, Ren J, Blake C et al. Obesity is associated with atypia in breast ductal lavage of women with proliferative breast disease. Cancer Epidemiol. 2009;33:242-8.
46. Jick SS, Walker AM, Jick H. Conjugated estrogens and fibrocystic breast disease. Am J Epidemiol 1986;124:746-51. (Pubitemid 17180488)
47. Trapido EJ, Brinton LA, Schairer C, Hoover R. Estrogen replacement therapy and benign breast disease. J Natl Cancer Inst 1984;73:1101-5. (Pubitemid 15216202)
48. Berkowitz GS, Kelsey JL, LiVolsi VA, Merino MJ, Holford TR, Hildreth NG et al. Exogenous hormone use and fibrocystic breast disease by histopathologic component. Int J Cancer 1984;34:443-9. (Pubitemid 14014107)
49. Berkowitz GS, Kelsey JL, Holford TR, LiVolsi VA, Merino MJ, Beck GJ et al. Estrogen replacement therapy and fibrocystic breast disease in postmenopausal women. Am J Epidemiol 1985;121:238-45. (Pubitemid 15158535)
50. Pastides H, Najjar MA, Kelsey JL. Estrogen replacement therapy and fibrocystic breast disease. Am J Prev Med 1987;3:282-6.
51. Canny PF, Berkowitz GS, Kelsey JL, LiVolsi VA. Fibroadenoma and the use of exogenous hormones:a case-control study. Am J Epidemiol 1988;127:454-61. (Pubitemid 18072863)
52. Harvey JA. Use and cost of breast imaging for postmenopausal women undergoing hormone replacement therapy. AJR Am J Roentgenol 1999;172:1615-9. (Pubitemid 29242349)
53. Rohan TE, Miller AB. Hormone replacement therapy and risk of benign proliferative epithelial disorders of the breast. Eur J Cancer Prev 1999;8:123-30. (Pubitemid 29210217)
54. Gayet A, Estève J, Séradour B, Piana L, Jacquemier J. Does hormone replacement therapy increase the frequency of breast atypical hyperplasia in postmenopausal women? Results from the Bouches du Rhone district screening campaign. Eur J Cancer 2003;39:1738-45. (Pubitemid 36897611)
55. Parazzini F, La Vecchia C, Franceschi S, Decarli A, Gallus G, Regallo M et al. Risk factors for pathologically confirmed benign breast disease. Am J Epidemiol 1984;120:115-22. (Pubitemid 14076733)
56. Ravnihar B, Seigel DG, Lindtner J. An epidemiologic study of breast cancer and benign breast neoplasias in relation to the oral contraceptive and estrogen use. Eur J Cancer 1979;15:395-405. (Pubitemid 9177170)
57. Bright RA, Morrison AS, Brisson J, Burstein NA, Sadowsky NL, Kopans DB et al. Histologic and mammographic specificity of risk factors for benign breast disease. Cancer 1989;64:653-7. (Pubitemid 19185215)
58. Tzingounis V, Cardamakis E, Ginopoulos P, Argiropoulos G. Incidence of benign and malignant breast disorders in women taking hormones (contraceptive pill or hormonal replacement therapy). Anticancer Res 1996;16:3997-4000. (Pubitemid 27084958)
59. Del Favero C, Rossini G, Tufarulo L, Ciancio ML, Sopransi M, Martegani A et al. Mammography changes associated with hormone replacement therapy in post-menopausal patients. Radiol Med 1997;93:210-3.
60. Finkelde DT, Kitchen PR, Hayes PR, McKinlay MR, Henderson MA. Symptomatic benign breast disease and hormone replacement therapy. Breast 2001;10:127-30. (Pubitemid 32390227)
61. Rippy L, Marsden JIs. HRT justified for symptom management in women at higher risk of developing breast cancer? Climacteric 2006;9:404-15. (Pubitemid 44691454)
62. Maclennan AH. HRT in difficult circumstances: are there any absolute contraindications? Climacteric 2011;14:409-17.
63. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer Lancet 1996;347:1713-27.
64. Cibula D, Gompel A, Mueck AO, La Vecchia C, Hannaford PC, Skouby SO et al. Hormonal contraception and risk of cancer. Hum Reprod Update 2010;16.631-50.
65. Pastides H, Kelsey JL, LiVolsi VA, Holford TR, Fischer DB, Goldenberg IS. Oral contraceptive use and fibrocystic breast disease with special reference to its histopathology. J Natl Cancer Inst 1983;71:5-9. (Pubitemid 13030522)
66. Hsieh CC, Crosson AW, Walker AM, Trapido EJ, MacMahon B. Oral contraceptive use and fibrocystic breast disease of different histologic classifications. J Natl Cancer Inst 1984;72:285-90. (Pubitemid 14198850)
67. Kelsey JL, Holford TR, White C, Mayer ES, Kilty SE, Acheson RM. Oral contraceptives and breast disease. An epidemiological study. Am J Epidemiol 1978;107:236-44. (Pubitemid 8313534)
68. Lees AW, Burns PE, Grace M. Oral contraceptives and breast disease in premenopausal Northern Albertan women. Int J Cancer 1978;22:700-7. (Pubitemid 9069789)
69. McGonigle KF, Huggins GR. Oral contraceptives and breast disease. Fertil Steril 1991;56:799-19.
70. Kaunitz AM. Oral contraceptive health benefits: perception versus reality. Contraception 1999;59:29S-33S. (Pubitemid 29174407)
71. Rohan TE, Miller AB. A cohort study of oral contraceptive use and risk of benign breast disease. Int J Cancer 1999;82:191-6. (Pubitemid 29293776)
72. Burkman RT, Collins JA, Schulman LP, Williams JK. Current perspectives on oral contraceptive use. Am J Obstet Gynecol 2001;185:S4-S12. (Pubitemid 32747855)
73. Vessey M, Yeates D. Oral contraceptives and benign breast disease: an update of findings in a large cohort study. Contraception 2007;76:418-24. (Pubitemid 350180740)
74. Ory H, Cole P, MacMahon B, Hoover R. Oral contraceptives and reduced risk of benign breast diseases. N Engl J Med 1976;294:419-22.
75. Sitruk-Ware R, Thalabard JC, Benotmane A, Mauvais-Jarvis P. Risk factors for breast fibroadenoma in young women. Contraception 1989;40:251-68. (Pubitemid 19222981)
76. Coriaty Nelson Z, Ray RM, Gao DL, Thomas DB. Risk factors for fibroadenoma in a cohort of female textile workers in Shanghai, China. Am J Epidemiol 2002;156:599-605.
77. Estevão RA, Nazário AC, Baracat EC. Effect of oral contraceptive with and without associated estriol on ultrasound measurements of breast fibroadenoma: randomized clinical trial. Sao Paulo Med J 2007;125:275-80.
78. Charreaul, Plu-Bureau G, Bachelot A, Contessa G, Guinebretiere JM, Le MG. Oral contraceptive use and risk of benign breast disease in a French case-control study of young women. Eur J Cancer Prev 1993;2:147-54.
79. Berkowitz GS, Kelsey JL, LiVolsi VA, Holford TR, Merino MJ, Ort S et al. Oral contraceptive use and fibrocystic breast disease among pre- and postmenopausal women. Am J Epidemiol 1984;120:87-96. (Pubitemid 14076730)
80. Williams JK. Noncontraceptive benefits of oral contraceptive use: an evidence-based approach. Int J Fertil Womens Med 2000;45:241-7. (Pubitemid 30470183)
81. Dayal M, Barnhart KT Noncontraceptive benefits and therapeutic uses of the oral contraceptive pill. Semin Reprod Med 2001;19:295-303. (Pubitemid 34028417)
82. Cedars MI. Triphasic oral contraceptives: review and comparison of various regimens. Fertil Steril 2002;77:1-14. (Pubitemid 34097439)
83. Schindler AE. Non-contraceptive benefits of hormonal contraceptives. Minerva Ginecol 2010;62:319-29.
84. Kaunitz AM. Oral contraceptive health benefits: perception versus reality. Contraception. 1999;59(1 Suppl):29S-33S. (Pubitemid 29174407)
85. Krämer EA, Seeger H, Krämer B, Wallwiener D, Mueck AO. ESHRE Capri Workshop Group. Noncontraceptive health benefits of combined oral contraception. Hum Reprod Update 2005;11:513-25.